Home > Reassuring real-world safety profile of 3 CGRP inhibitors

Reassuring real-world safety profile of 3 CGRP inhibitors

Presented By
Prof. Stephen D. Silberstein, Thomas Jefferson University, PA, USA
EAN 2020
The 3 calcitonin gene-related peptide (CGRP) inhibitors that have been approved thus far for the prevention of migraine since 2018 —erenumab, fremanezumab, and galcanezumab— showed a reassuring safety profile in a real-world setting [1]. Post-marketing data of the first 6 months following their marketing launch was reported. Included in this retrospective analysis were adverse events (AEs) that were spontaneously reported to the FDA during the first 6 months post-approval and that were likely to be treatment-related. Many of the reported AEs were injection-site reactions, such as pain, pruritus, rash, and erythema. Migraine, headache, and drug ineffectiveness were reported for all 3 medications. Constipation ranked second for erenumab, but was not in the top 10 of AEs for fremanezumab or galcanezumab. Cardiovascular events were not among the top 10 AEs for any of the products. The top 5 reporting rates (RRs) per 1,000 patients exposed for each of the 3 CGR...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on